Glycogen synthase kinase 3β (GSK‐3β) and casein kinase 1δ (CK‐1δ) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson's disease. An inhibitor able to target these two kinases was developed by docking‐based design. Compound 12, 3‐(7‐amino‐5‐(cyclohexylamino)‐[1,2,4]triazolo[1,5‐a][1,3,5]triazin‐2‐yl)‐2‐cyanoacrylamide, showed combined inhibitory activity against GSK‐3β and CK‐1δ [IC50(GSK‐3β)=0.17 μm; IC50(CK‐1δ)=0.68 μm]. In particular, classical ATP competition was observed against CK‐1δ, and a co‐crystal of compound 12 inside GSK‐3β confirmed a covalent interaction between the cyanoacrylamide warhead and Cys199, which could help in the development of more potent covalent inhibitors of GSK‐3β. Preliminary studies on in vitro models of Parkinson's disease revealed that compound 12 is not cytotoxic and shows neuroprotective activity. These results encourage further investigations to validate GSK‐3β/CK‐1δ inhibition as a possible new strategy to treat neuroinflammatory/degenerative diseases.

A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition

Redenti, Sara;Marcovich, Irene;De Zorzi, Rita;Spalluto, Giampiero;Federico, Stephanie
2019

Abstract

Glycogen synthase kinase 3β (GSK‐3β) and casein kinase 1δ (CK‐1δ) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson's disease. An inhibitor able to target these two kinases was developed by docking‐based design. Compound 12, 3‐(7‐amino‐5‐(cyclohexylamino)‐[1,2,4]triazolo[1,5‐a][1,3,5]triazin‐2‐yl)‐2‐cyanoacrylamide, showed combined inhibitory activity against GSK‐3β and CK‐1δ [IC50(GSK‐3β)=0.17 μm; IC50(CK‐1δ)=0.68 μm]. In particular, classical ATP competition was observed against CK‐1δ, and a co‐crystal of compound 12 inside GSK‐3β confirmed a covalent interaction between the cyanoacrylamide warhead and Cys199, which could help in the development of more potent covalent inhibitors of GSK‐3β. Preliminary studies on in vitro models of Parkinson's disease revealed that compound 12 is not cytotoxic and shows neuroprotective activity. These results encourage further investigations to validate GSK‐3β/CK‐1δ inhibition as a possible new strategy to treat neuroinflammatory/degenerative diseases.
15-gen-2019
Pubblicato
https://onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201800778
File in questo prodotto:
File Dimensione Formato  
Redenti_et_al-2019-ChemMedChem.pdf

non disponibili

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 851.78 kB
Formato Adobe PDF
851.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
cmdc201800778-sup-0001-misc_information.pdf

non disponibili

Descrizione: Supporting information
Tipologia: Altro materiale allegato
Licenza: Copyright Editore
Dimensione 3.66 MB
Formato Adobe PDF
3.66 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
2935106_cmdc201800778-sup-0001-misc_information-PostPrint.pdf

accesso aperto

Descrizione: Post Print VQR3
Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 4.28 MB
Formato Adobe PDF
4.28 MB Adobe PDF Visualizza/Apri
2935106_Redenti_et_al-2019-ChemMedChem-PostPrint.pdf

accesso aperto

Descrizione: Post Print VQR3
Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/2935106
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 12
social impact